GRMLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as GRMLW

Greenland Mines Ltd

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 17, 2026

$5.61−0.39 (-6.50%)

Close on Oct 19, 2026

Market cap: $709.78M
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Greenland Mines has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Greenland Mines filed with the SEC

Aug 27, 2026, 5:00 PM ET
LAUNCH PRESS RELEASE DATED AUGUST 25, 2026
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aug 27, 2026, 5:00 PM ET
PRICING PRESS RELEASE DATED AUGUST 26, 2026
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Jul 23, 2026, 9:00 AM ET
Greenland Mines Announces Limited-Duration Stockholder
Material agreement · Other events · EX-99.1 to Form 8-K
Jul 20, 2026, 4:30 PM ET
Greenland Mines Reports 36-44% PdEq Grade Uplift and +31% Increase
Regulation FD disclosure · EX-99.1 to Form 8-K
May 14, 2026, 11:22 AM ET
INVESTOR PRESENTATION DATED MAY 14, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
May 14, 2026, 11:22 AM ET
PRESS RELEASE DATED MAY 13, 2025
Regulation FD disclosure · EX-99.2 to Form 8-K
Mar 23, 2026, 3:09 PM ET
Greenland Mines Secures Additional 180-Day
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mar 16, 2026, 12:32 PM ET
MARCH 12, 2026 PRESS RELEASE
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Mar 12, 2026, 4:00 PM ET
INVESTOR PRESENTATION DATED MARCH 12, 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Mar 4, 2026, 4:30 PM ET
NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT
Regulation FD disclosure · EX-99.1 to Form 8-K
Aug 12, 2025, 4:46 PM ET
Klotho Neurosciences, Inc. (KLOTHO) Initiates Manufacturing of KLTO-202
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 22, 2025, 5:00 PM ET
Klotho Neurosciences, Inc. Partners with AAVnerGene
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 18, 2025, 5:10 PM ET
Klotho Neurosciences, Inc. Regains Full Compliance with NASDAQ Minimum
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Jul 10, 2025, 5:12 PM ET
Klotho Neurosciences, Inc. Granted FDA Orphan Drug Designation for
Regulation FD disclosure · EX-99.1 to Form 8-K
Jun 30, 2025, 5:20 PM ET
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy
Regulation FD disclosure · EX-99.1 to Form 8-K
Jun 16, 2025, 9:00 AM ET
Neurosciences Raises Over $11 Million, Retires All Debt,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Jun 10, 2025, 11:58 AM ET
KLOTHO NEUROSCIENCE, INC. ANNOUNCES AN APPROACH
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Oct 2, 2024, 12:30 PM ET
PRESS RELEASE DATED SEPTEMBER 30, 2024
Other events · EX-99.1 to Form 8-K
Jun 20, 2024, 1:14 PM ET
AUDITED FINANCIAL STATEMENTS OF ANEW MEDICAL, INC. FOR THE FISCAL YEARS ENDED DECEMBER 31, 2022 AND DECEMBER 31, 2023
Other events · EX-99.1 to Form 8-K
Jun 20, 2024, 1:14 PM ET
UNAUDITED FINANCIAL STATEMENTS OF ANEW MEDICAL, INC. FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024
Other events · EX-99.2 to Form 8-K
Aug 11, 2023, 3:24 PM ET
INVESTOR PRESENTATION OF ANEW MEDICAL, INC., DATED AUGUST 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
Jun 2, 2023, 9:40 PM ET
PRESS RELEASE, DATED MAY 30, 2023
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Apr 27, 2022, 5:00 PM ET
UNAUDITED PRO FORMA BALANCE SHEET DATED APRIL 7, 2022
Unregistered share sale · Other events · EX-99.1 to Form 8-K
Apr 21, 2022, 5:17 PM ET
BALANCE SHEET DATED APRIL 4, 2022
Other events · EX-99.1 to Form 8-K